Physician profile
Lance Kim
NPI 1366411514
$1,042,518.30
in general payments reported to CMS, 2019-2025
97 companies · $127K in 2025
The $127K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155K · 2020: $159K · 2021: $192K · 2022: $160K · 2023: $123K · 2024: $128K · 2025: $127K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $197K · Honoraria: $94K · Food and Beverage: $34K · Consulting Fee: $27K · Travel and Lodging: $26K · Education: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $196,687.85 |
| Honoraria | $93,937.50 |
| Food and Beverage | $34,034.34 |
| Consulting Fee | $26,774.30 |
| Travel and Lodging | $25,590.08 |
| Education | $444.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $121,157.26 | 2020-2025 | Xcopri |
| E.R. Squibb & Sons, L.L.C. | $113,389.78 | 2020-2025 | Zeposia |
| Lundbeck LLC | $95,067.64 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $90,589.25 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbvie INC. | $80,114.84 | 2021-2025 | |
| Biogen, INC. | $77,529.43 | 2019-2024 | Vumerity, Tysabri |
| Amgen INC. | $68,523.25 | 2019-2022 | |
| Lilly USA, LLC | $44,694.41 | 2019-2025 | Emgality, Kisunla, Zepbound |
| Tg Therapeutics, INC. | $44,425.89 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $42,120.16 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $33,297.44 | 2023-2025 | Nuplazid, Daybue |
| Impel Pharmaceuticals INC. | $27,563.15 | 2022-2023 | Trudhesa |
| Eisai INC. | $25,809.65 | 2019-2025 | |
| Celgene Corporation | $25,782.42 | 2019-2025 | Zeposia |
| Corium, LLC | $23,279.74 | 2022-2023 | Adlarity |
Show all 96 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $20,600.34 | 2019-2022 | |
| Allergan, INC. | $19,987.26 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19,133.14 | 2022 | |
| Harmony Biosciences LLC | $15,399.92 | 2020-2025 | |
| Mdd US Operations, LLC | $15,369.93 | 2019-2024 | Gocovri |
| Avadel Cns Pharmaceuticals, LLC | $8,636.58 | 2023-2025 | Lumryz |
| C2n Diagnostics, LLC | $5,427.74 | 2025 | Precivityad2 |
| Banner Life Sciences, LLC | $2,529.49 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $1,910.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,866.22 | 2019-2025 | |
| Genentech, INC. | $1,819.86 | 2022 | |
| Ucb, INC. | $1,306.48 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Pfizer INC. | $1,047.82 | 2019-2025 | |
| Nevro Corp. | $1,039.31 | 2021-2023 | Senza |
| Boston Scientific Corporation | $964.17 | 2020-2025 | Vercise, General - Dbs |
| Greenwich Biosciences, INC. | $948.39 | 2019-2021 | |
| Argenx US, INC. | $873.91 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $694.81 | 2021-2025 | Caplyta |
| Genzyme Corporation | $645.32 | 2019-2025 | |
| Strongbridge US INC. | $597.12 | 2019-2020 | |
| Promius Pharma LLC | $536.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $504.25 | 2020-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $501.45 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Neurocrine Biosciences, INC. | $400.06 | 2020-2023 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $391.74 | 2019-2024 | Inbrija, Ampyra |
| Axsome Therapeutics, INC. | $371.00 | 2022-2025 | Sunosi, Auvelity, Symbravo |
| Abbott Laboratories | $354.51 | 2022 | |
| Emd Serono, INC. | $349.58 | 2019-2025 | |
| Grifols USA, LLC | $326.38 | 2019-2025 | Gamunex-C, Xembify |
| Philips North America LLC | $303.54 | 2019-2024 | (Ap7) Ambition 1 5t S |
| Amneal Pharmaceuticals LLC | $259.42 | 2020-2025 | Crexont, Lyvispah, Rytary |
| Csl Behring | $246.98 | 2019-2025 | Hizentra |
| Vanda Pharmaceuticals INC. | $244.28 | 2020-2025 | Fanapt, Ponvory, Hetlioz |
| Sonex Health, INC. | $241.30 | 2025 | Sx-One Microknife |
| Alnylam Pharmaceuticals INC. | $220.90 | 2020-2023 | Onpattro |
| Idorsia Pharmaceuticals US INC | $197.98 | 2022-2023 | Quviviq |
| Watermark Medical, INC. | $180.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $179.86 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $168.67 | 2024 | Echelon Oval |
| Tanabe Pharma America, INC. | $157.33 | 2019-2025 | Radicava |
| Siemens Medical Solutions USA, INC. | $145.44 | 2024 | Magnetom Altea |
| Medtronic USA, INC. | $141.94 | 2019 | |
| Sumitomo Pharma America, INC. | $130.45 | 2023-2024 | Aptiom |
| Vertical Pharmaceuticals, LLC | $128.00 | 2019-2020 | |
| Acelrx Pharmaceuticals, INC. | $124.97 | 2019 | |
| Nalu Medical, INC. | $122.18 | 2022 | |
| Avanir Pharmaceuticals, INC. | $118.33 | 2019 | |
| Cala Health, INC. | $114.90 | 2025 | Cala Kiq |
| Neurelis, INC. | $111.72 | 2020-2024 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $106.12 | 2023-2024 | Fycompa |
| Painteq LLC | $87.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $79.85 | 2019 | |
| Arbor Pharmaceuticals, INC. | $78.76 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $75.49 | 2021-2025 | Keveyis |
| Merz Pharmaceuticals, LLC | $70.87 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Livanova USA, INC. | $63.91 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Zyla Life Sciences, INC. | $59.35 | 2019 | |
| Impel Pharmaceuticals LLC | $43.80 | 2025 | Trudhesa |
| 3b Medical, INC. | $42.85 | 2024 | Luna |
| Fisher & Paykel Healthcare INC | $35.18 | 2023-2024 | Fisher & Paykel Healthcare |
| Aprecia Pharmaceuticals, LLC | $31.19 | 2022 | |
| Alkermes, INC. | $23.45 | 2025 | Lybalvi |
| Horizon Therapeutics Plc | $20.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.84 | 2022 | |
| Microtransponder, INC. | $19.03 | 2025 | |
| Tactile Systems Technology INC | $18.69 | 2023 | Flexitouch Plus, Entre Plus |
| Aquestive Therapeutics, INC. | $18.32 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.88 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.72 | 2019 | |
| Grt US Holding, INC. | $16.55 | 2022 | |
| Akcea Therapeutics, INC. | $15.77 | 2019 | |
| Biodelivery Sciences International, INC. | $15.62 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.93 | 2021 | |
| Upsher-Smith Laboratories LLC | $14.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.82 | 2020 | |
| Currax Pharmaceuticals LLC | $14.75 | 2021 | |
| Merck Sharp & Dohme LLC | $14.62 | 2021 | |
| Avion Pharmaceuticals | $14.41 | 2022 | |
| Aucta Pharmaceuticals, INC. | $13.03 | 2024 | Motpoly Xr |
| Medtronic Vascular, INC. | $12.53 | 2019 | |
| Ge Healthcare | $11.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$954,916.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.